research reports and media, page-3624

Which should reassuringly address @strangelogic 's concerns about "competing claims down the track" because ultimately we have supply from Bene for a range of indications.

The original supply agreement info from the $PAR prospectus provided for exclusive supply within specific territories, and specific fields. These fields, at the very beginning, included "Bone Marrow Edema, Asthma, Rhinitis and Chronic Obstructive Pulmonary Disease.

Then in the September 2020 ann. regarding the enhancement of the supply agreement (screenshot below) we expanded these even further (it was speculated at the time that the expanded indications meant the inclusion of ARDS and Heart Failure - but we weren't provided specifics).


There are also our patents, of course. In fact it could be riskier for Arthropharm to try to cross these lines than almost anyone else, because the supply of their own API from Bene for veterinary product could be put at risk. It did definitely make me wonder what the game was though, when I saw their name attached to the MDPI release.